Next report date
Report period
Q1 2024
EPS estimate
−0.15USD
Revenue estimate
—
−1.61USD
−30.54 MUSD
675.00 KUSD
24.99 M
About Unicycive Therapeutics, Inc.
Sector
Industry
CEO
Shalabh Gupta
Website
Headquarters
Los Altos
Employees (FY)
14
Founded
2016
FIGI
BBG01163JG34
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of UNCY is 0.99 USD — it has decreased by 5.26% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unicycive Therapeutics, Inc. stocks are traded under the ticker UNCY.
Unicycive Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
UNCY stock is 7.11% volatile and has beta coefficient of 0.57. Check out the list of the most volatile stocks — is Unicycive Therapeutics, Inc. there?
UNCY earnings for the last quarter are −0.13 USD per share, whereas the estimation was −0.11 USD resulting in a −18.18% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Unicycive Therapeutics, Inc. earnings.
Yes, you can track Unicycive Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
UNCY stock has fallen by 13.19% compared to the previous week, the month change is a 35.60% fall, over the last year Unicycive Therapeutics, Inc. has showed a 32.05% decrease.
UNCY net income for the last quarter is −7.80 M USD, while the quarter before that showed −4.33 M USD of net income which accounts for −79.97% change. Track more Unicycive Therapeutics, Inc. financial stats to get the full picture.
Today Unicycive Therapeutics, Inc. has the market capitalization of 36.15 M, it has increased by 2.68% over the last week.
No, UNCY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, UNCY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unicycive Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 14.00 employees. See our rating of the largest employees — is Unicycive Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unicycive Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unicycive Therapeutics, Inc. stock shows the sell signal. See more of Unicycive Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Unicycive Therapeutics, Inc. future price: according to them, UNCY price has a max estimate of 9.00 USD and a min estimate of 3.00 USD. Read a more detailed Unicycive Therapeutics, Inc. forecast: see what analysts think of Unicycive Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Unicycive Therapeutics, Inc. EBITDA is −20.49 M USD, and current EBITDA margin is −3.04 K%. See more stats in Unicycive Therapeutics, Inc. financial statements.